A multinational European survey on the in-vitro activity of rufloxacin and other comparative antibiotics on respiratory and urinary bacterial pathogens

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 4, 1996, Pages 627-639

  Schito, G C ^a,k   Acar, J F ^c   Bauernfeind, A ^e   Duval, J ^d   Finch, R G ^j   Focht, J ^f   Nicoletti, G ^b   Phillips, I ^k   Pratts, G ^h   Soriano, F ⁱ   Wiedeman, B ^g   Wise, R ^l  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c SAINT JOSEPH HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITY OF MUNICH   (Germany)

^f Bioscientia Center for Human Genetics   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^j UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^k ST THOMAS HOSPITAL   (United Kingdom)

^l CITY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFIXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; GENTAMICIN; NORFLOXACIN; QUINOLONE; RUFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA; NONHUMAN; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; URINARY TRACT INFECTION;

EID: 10544237681     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.4.627     Document Type: Article

References (22)

1. Aguiar, J. M., Chacon, J., Canton, R. & Baquero, F. (1992). The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections. Antimicrobial Agents and Chemotherapy 29, 349-50.
2. Aguilar, L., Balcabao, I. P., Salvá, P., Martin, M., Costa, J., Prieto, J. et al. (1996). Ex vivo antibacterial properties of rufloxacin in healthy volunteers. Comparative study versus norfloxacin. Antimicrobial Agents and Chemotherapy, in press.
3. Bach, D., van den Berg-Segers, A., Hübner, A., van Breukelen, G., Cesana, M. & Plétan, Y. (1995). Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis. Journal of Urology 154, 19-24.
4. Boerema, J. B., Bach, D., Jol, C. & Pahlmann, W. (1991). Penetration of rufloxacin into human prostatic tissue and fluid. Journal of Antimicrobial Chemotherapy 28, 547-54.
5. Boerema, J. B., Bischoff, W., Focht, J. & Naber, K. G. (1991). An open multicentre study on the efficacy and safety of rufloxacin in patients with chronic bacterial prostatitis. Journal of Antimicrobial Chemotherapy 28, 587-97.
6. Cogo, R., Rimoldi, R., Mattina, R. & Imbimbo, B. P. (1992). Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections. Therapeutic Drug Monitoring 14, 36-41.
7. Dirksen, M., Focht, J. & Boerema, J. (1991). Rufloxacin once daily in acute exacerbations of chronic bronchitis. Infection 19, 297-300.
8. Furneri, P. M., Bazzano, M., Campo, L., Cesana, M. & Tempera, G. (1994a). In vitro activity of rufloxacin against Listeria monocytogenes, Legionella pneumophila, and Chlamydia trachomatis. Chemotherapy 40, 104-8.
9. Furneri, P. M., Bisignano, G., Cerniglia, G., Nicoletti, G., Cesana, M. & Tempera, G. (1994b). In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922. Antimicrobial Agents and Chemotherapy 38, 2651-4.
10. Jardin, A., Cesana, M. and the French Multicenter UTI-Rufloxacin Group. (1995). Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. Antimicrobial Agents and Chemotherapy 39, 215-20.
11. Kisicki, J. C., Griess, R. S., Ott, C. L., Cohen, G. M., McCormack, R. J. & Troetel, W. M. (1992). Imbimbo BP. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers. Antimicrobial Agents and Chemotherapy 36, 1296-301.
12. Klietmann, W., Cesana, M., Rondel, R. K. & Focht, J. (1993). Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis. Antimicrobial Agents and Chemotherapy 37, 2298-306.
13. Kresken, M., Hafner, D., Mittermayer, H., Verbist, L., Bergogne-Berezin, E., Giamarellou, H. et al. (1994). Prevalence of fluoroquinolone resistance in Europe. Infection 22, Suppl. 2, 90-8.
14. Mattina, R., Cocuzza, C. E., Cesana, M., and the Italian UTI-Rufloxacin Group. (1993). Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Infection 21, 106-11.
15. Mattina, R., Cocuzza, C. E., Cesana, M. & Bonfiglio, G. (1991). In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates. Chemotherapy 37, 260-9.
16. National Committee for Clinical Laboratory Standards. (1993). Methods for Diluition Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved Standard-Third Edition: M7-A3. NCCLS, Villanova, PA.
17. Pérez-Trallero, E., Urbieta, M., Jimenez, D., Gàrcia-Arenzana, J. M., Cilla, G. (1993). Ten-year survey of quinolone resistance in Escherichia coli causing urinary-tract infections. European Journal of Clinical Microbiology and Infectious Disease 12, 349-51.
18. Phillips, I., Baquero, F., Bergan, T., Degener, J., Schito, G. C., Wiedemann, B. and the European Study Group on Antibiotic Breakpoints. (1993). Breakpoint determination rufloxacin. European Journal of Clinical Microbiology and Infectious Disease 12, 574-5.
19. Ravizzola, G., Pinsi, G., Pirali, F., Colombrita, D., Foresti, I., Peroni, L. et al. (1989). Rufloxacin (MF 934): in vitro and in vivo antibacterial activity. Drugs under Experimental and Clinical Research 15, 11-5.
20. Wise, R., Andrews, J. M., Imbimbo, B. P., Greaves, I. & Honeybourne, D. (1993). The penetration of rufloxacin into sites of potential infection in the respiratory tract. Journal of Antimicrobial Chemotherapy 32, 861-6.
21. Wise, R., Andrews, J. M., Matthews, R. & Wolstenholme, M. (1992). The in-vitro activity of two new quinolones: rufloxacin and MF 961. Journal of Antimicrobial Chemotherapy 29, 649-60.
22. Wise, R., Johnson, J., O'Sullivan, N., Andrews, J. M. & Imbimbo, B. P. (1991). Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J ournal of Antimicrobial Chemotherapy 28, 905-9.